Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

한국어

JW SHINYAK CORPORATION

JW신약067290KOSDAQSector: Pharma & Biotech
₩3,43010.65%Market cap ₩192.2BAs of Sep 3, 2026 close · updated once daily
Market cap
₩192.2B
#407 in KOSDAQ
10.7x
Sector median 16.3x (profitable cos.)
4.11x
Sector median 1.61x
0.0%
Sector median 0.0%
B
Grade B56.3 ptsTop 42% of 2,523 graded stocksMethodology v2.0

As of Sep 3, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCurrentCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band B with a total score of 56.3 points.

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩1,254High ₩3,430
Latest close
Price change by period
1W
72.30%
1M
77.10%
3M
153.30%
1Y
129.20%

As of the Sep 3, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

71.5/100
How much debt does it carry relative to equity?
43.0%
Sector median 51.6%
Sector lowhighTop 39.1% in sector
Can it cover what's due within a year?
169.3%
Sector median 191.7%
Sector lowhighBottom 46.4% in sector
How much of revenue becomes profit?
9.2%
Sector median -2.4%
Sector lowhighTop 20.7% in sector
How much did it earn on its own capital?
38.4%
Sector median -4.5%
Sector lowhighTop 0.6% in sector

Source filing: annual report (consolidated) — view original

2

Growth momentum

35.0/100
How much did revenue grow in a year?
-12.9%
Sector median 6.4%
Sector lowhighBottom 16.1% in sector
Has it grown steadily over three years?
-7.6%
Sector median 4.9%
Sector lowhighBottom 19.5% in sector
Did core profits grow in a year?
-25.1%
Sector median 3.6%
Sector lowhighBottom 26% in sector
Are core profits higher than three years ago?
73.9%
Sector median 3.5%
Sector lowhighTop 21.8% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original

3

Price attractiveness

56.9/100
Is the price expensive relative to earnings?
10.7x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 14% in sector
Is the price expensive relative to book value?
4.11x
Sector median 1.61x
Sector lowhighBottom 27.7% in sector

Valuation uses the Sep 3, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
156,578 shares (0.2% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 5 met · 4 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩15.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩6B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
7.7% → 24.8%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩6B vs ₩15.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
57.9% → 30.1%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
84.0% → 169.3%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
50,841,502 → 53,376,126
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
10.7% → 9.2%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
1.42x → 1.29x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Private CB/BW issuance resolutions (past 36 months)

2 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2026-05-21). View filing

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source
Convertible bond issuanceMay 21, 2026Source
Periodic report filedMay 15, 2026Source

View in the filings calendar →